{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-cancer-care-pain/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"42928747-95fa-57d3-ae9e-7e3a6cf476a5","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 6468a551-18d5-4377-9ee1-e281039838ae --><h2>Update</h2><!-- end field 6468a551-18d5-4377-9ee1-e281039838ae -->","summary":null,"htmlStringContent":"<!-- begin item b47caf32-f60e-4df0-bcff-414b884f9bc2 --><!-- end item b47caf32-f60e-4df0-bcff-414b884f9bc2 -->","topic":{"id":"bc60f031-53af-530c-93e6-59feeef85bcb","topicId":"305b6c55-5a1b-4817-87a1-c88490ac688b","topicName":"Palliative cancer care - pain","slug":"palliative-cancer-care-pain","lastRevised":"Last revised in September 2020","chapters":[{"id":"edd133a3-7ad6-5893-82e6-230eb9313dd3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6c915659-224b-530e-9fb3-c0b95720d118","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"362828da-ca6f-5900-8441-afd9ea44af5b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"cd526925-546a-5aac-93eb-485967fb5fd7","slug":"changes","fullItemName":"Changes"},{"id":"42928747-95fa-57d3-ae9e-7e3a6cf476a5","slug":"update","fullItemName":"Update"}]},{"id":"30edbf0f-7363-5f35-8126-77659a917fa3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"21b41383-eea4-5b71-8b34-687f05a65a5d","slug":"goals","fullItemName":"Goals"},{"id":"6ae0a52d-6ca2-5d97-8aa0-2beccf699f7e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d2aefa77-c551-539d-be41-67260cbe43ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bc8c749-a90c-532b-854e-5ee96116de81","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cf494151-3dcb-5990-851a-dd1cd70fab0c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9b0ea843-6c18-543c-b4f3-cbf22a737e5a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1078edd0-49b8-514b-aa1f-462d95bcb62c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"203a281c-b6df-5d53-a704-aae8df1662a6","slug":"definition","fullItemName":"Definition"},{"id":"7842468e-5e33-52dc-ade6-5149de1e1436","slug":"origins-of-pain","fullItemName":"Origins of pain"},{"id":"cc8e90f5-0cd6-54d0-9bec-75e0729d34b2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"288e99e9-418d-5e10-8b3b-94d111f68f63","fullItemName":"Management","slug":"management","subChapters":[{"id":"377406aa-05e6-5559-9f6e-4404453e407c","slug":"acute-severe-pain","fullItemName":"Scenario: Acute severe pain"},{"id":"3bc406e3-6db0-5386-a1a1-94f551e50a8d","slug":"assessment-of-pain","fullItemName":"Scenario: Assessment of pain"},{"id":"bfa2c711-266a-5133-a082-0655b9243bb5","slug":"managing-pain-non-emergency","fullItemName":"Scenario: Managing pain - non-emergency"},{"id":"fe447a1c-0019-5592-92ea-3d018c455b3b","slug":"managing-neuropathic-pain","fullItemName":"Scenario: Managing neuropathic pain"},{"id":"ffae5598-ad34-57a7-bb50-018dcb5f63c8","slug":"managing-intracranial-pressure-pain","fullItemName":"Scenario: Managing intracranial pressure pain"},{"id":"43317aee-6f8f-5d85-afed-94ec4c221bc5","slug":"managing-colic","fullItemName":"Scenario: Managing colic"},{"id":"4f3f67af-bf6a-5f02-84e4-c48ecc292167","slug":"managing-bone-pain","fullItemName":"Scenario: Managing bone pain"},{"id":"5c6257ce-9559-5775-a6e4-13eceaacff04","slug":"managing-muscle-spasm-pain","fullItemName":"Scenario: Managing muscle spasm pain"},{"id":"dba15959-96fa-5968-81ac-b3eb2b17604e","slug":"spinal-cord-compression","fullItemName":"Scenario: Spinal cord compression"},{"id":"d4083f8f-2904-55e8-9cb5-b20f6fcf10d2","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"}]},{"id":"32fe1b7d-4328-56b2-9102-e26bc06c421d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6452b6ef-626b-552e-bf5c-0c21daf91352","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2ca1fa6a-d245-53df-a4e5-79f63db752f1","slug":"codeine-dihydrocodeine-tramadol","fullItemName":"Codeine, dihydrocodeine and tramadol"},{"id":"9d55dc66-3dff-524e-9ed1-7919aeca221b","slug":"strong-opioids","fullItemName":"Strong opioids"},{"id":"47ef042e-05dc-576a-81b5-e9d12888c2e8","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"e39f9314-9fbb-5007-a7cf-c5ac3776546b","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"25156d8c-bb99-5e69-bf39-538e1a2c0265","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"58fbb7ca-b553-553e-8038-39021cfa2440","slug":"dexamethasone","fullItemName":"Dexamethasone"},{"id":"2e657be1-22f8-5617-85b0-b0d657de037e","slug":"diazepam","fullItemName":"Diazepam"},{"id":"d07c8c77-b362-533f-8d19-5397cdb2c2a6","slug":"baclofen","fullItemName":"Baclofen"},{"id":"e56de34b-8fb3-5a88-88fd-52f21822c95e","slug":"hyoscine-butylbromide","fullItemName":"Hyoscine butylbromide"}]},{"id":"ba95315f-c704-52b3-8e69-b66132db1afc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"36e5ad13-c74b-5b5b-a91a-dc99c76fe16c","slug":"drugs-to-treat-neuropathic-pain","fullItemName":"Drugs to treat neuropathic pain"}]},{"id":"e0efe998-f4e8-511b-9d28-24afd40c557e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"de1ea0e8-6fc9-51d7-85ca-027ba77b3439","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"db05b928-3724-5155-8572-4a5741697b59","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"ad310ea3-10a0-5123-a3cb-4623f775c2a6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ae075009-b5ea-57cb-9dab-2d35fa7facb1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"103ff2fc-2fa3-5785-a596-c4145bf1037f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"445d177d-22b8-5eef-aeaf-b7b0ae34c259","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"362828da-ca6f-5900-8441-afd9ea44af5b","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"6d34040a-7b2c-5eca-b5b5-1531b907e23c","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field efb9f5ae-6ea3-45ad-8a79-42e30dffcb2d --><h3>New evidence</h3><!-- end field efb9f5ae-6ea3-45ad-8a79-42e30dffcb2d -->","summary":null,"htmlStringContent":"<!-- begin item 8afdba59-a402-43ca-9c15-3f49865ea31a --><!-- begin field cd2075b0-aff4-432d-8cca-8ceec71c1811 --><h3>Evidence-based guidelines</h3><!-- end field cd2075b0-aff4-432d-8cca-8ceec71c1811 --><!-- begin field 799e35cc-9e69-4e2d-abca-b09f15da6613 --><p>No new evidence-based guidelines since 1 October 2016.</p><!-- end field 799e35cc-9e69-4e2d-abca-b09f15da6613 --><!-- begin field d4e6819b-ae06-4df4-bc43-142a1be00035 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field d4e6819b-ae06-4df4-bc43-142a1be00035 --><!-- begin field 2aac98c3-ee4f-4e5e-b763-86fdfa98b00d --><p>No new HTAs since 1 October 2016.</p><!-- end field 2aac98c3-ee4f-4e5e-b763-86fdfa98b00d --><!-- begin field 93d7be9d-fa24-4d75-911a-6c7b9ad8b6fe --><h3>Economic appraisals</h3><!-- end field 93d7be9d-fa24-4d75-911a-6c7b9ad8b6fe --><!-- begin field 40ad9ab4-217d-429b-856f-89dddd307d0e --><p>No new economic appraisals relevant to England since 1 October 2016.</p><!-- end field 40ad9ab4-217d-429b-856f-89dddd307d0e --><!-- begin field 1836f3a8-b6ea-42c8-ae32-54caf1b9f988 --><h3>Systematic reviews and meta-analyses</h3><!-- end field 1836f3a8-b6ea-42c8-ae32-54caf1b9f988 --><!-- begin field 374feeb9-3ea1-47fd-8eec-1c88a406ec5b --><ul><li>Schmidt-Hansen, M., Bennett, M. I., Arnold, S. et al. (2017) <em>Oxycodone for cancer-related pain</em>. The Cochrane Library.</li><li>Els, C., Jackson, T.D., Kunyk, D., et al. (2018) <em>Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews</em>. The Cochrane Library. [<a data-hyperlink-id=\"4a7b6ffd-8a73-433b-925f-a98200ba3cbf\" href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD012509.pub2/full\">Free Full-Text</a>]</li><li>Skjødt, M. K., et al. (2018) <em>Side effects of drugs for osteoporosis and metastatic bone disease. </em>British Pharmacological Society. [<a data-hyperlink-id=\"497a3435-a418-412d-a2f4-a98200ba3dbb\" href=\"https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13759\">Free Full-text</a>]</li></ul><!-- end field 374feeb9-3ea1-47fd-8eec-1c88a406ec5b --><!-- begin field bca67d87-dc6f-4fa8-b114-859ab64135bf --><h3>Primary evidence</h3><!-- end field bca67d87-dc6f-4fa8-b114-859ab64135bf --><!-- begin field 9d4e5d78-8381-45bf-82a4-3a0e4d4cbc6a --><p>No new randomized controlled trials published in the major journals since 1 October 2016.</p><!-- end field 9d4e5d78-8381-45bf-82a4-3a0e4d4cbc6a --><!-- end item 8afdba59-a402-43ca-9c15-3f49865ea31a -->","subChapters":[]},{"id":"cf570f06-110f-563d-a281-3b27d62aba49","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 08138110-0559-4707-ad9f-af08f4e51879 --><h3>New policies</h3><!-- end field 08138110-0559-4707-ad9f-af08f4e51879 -->","summary":null,"htmlStringContent":"<!-- begin item 51d8ad8a-3897-4c4e-a75c-809bcb292fb4 --><!-- begin field 55cf2746-10fc-433a-a72d-b43f21b1b20c --><p>No new national policies or guidelines since 1 October 2016.</p><!-- end field 55cf2746-10fc-433a-a72d-b43f21b1b20c --><!-- end item 51d8ad8a-3897-4c4e-a75c-809bcb292fb4 -->","subChapters":[]},{"id":"c77ec610-fb03-5605-a1c7-f1f4978af748","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field 8eb0a611-4c7a-4316-942b-cbb348808b13 --><h3>New safety alerts</h3><!-- end field 8eb0a611-4c7a-4316-942b-cbb348808b13 -->","summary":null,"htmlStringContent":"<!-- begin item de5d3215-d1fd-4c72-a48e-56410438a44d --><!-- begin field 9114bdcf-7098-4128-8e4b-375f22d4a692 --><p>No new safety alerts since 1 October 2016.</p><!-- end field 9114bdcf-7098-4128-8e4b-375f22d4a692 --><!-- end item de5d3215-d1fd-4c72-a48e-56410438a44d -->","subChapters":[]},{"id":"52d00833-81fa-54f9-917b-b4d3a8dab856","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field 0b2e14d0-f51d-4ee1-afb5-f458a0f92aca --><h3>Changes in product availability</h3><!-- end field 0b2e14d0-f51d-4ee1-afb5-f458a0f92aca -->","summary":null,"htmlStringContent":"<!-- begin item d1af68e9-e9ee-4f07-9637-e2466fc84852 --><!-- begin field cba52edc-0295-4ed9-9c99-aba16735b82b --><ul><li>Pridinol (Myopridin) is licensed for central and peripheral muscle spasms including lumbar pain, torticollis, and general muscle pain. It acts on alpha motor neurones in the spine to relieve skeletal muscle tension of both central and peripheral origin. See more <a href=\"https://www.mims.co.uk/new-muscle-spasm-treatment-option/musculoskeletal-disorders/article/1704164\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"a64af4b4-6922-4831-a472-acb400cfe1d9\">here</a>.</li></ul><!-- end field cba52edc-0295-4ed9-9c99-aba16735b82b --><!-- end item d1af68e9-e9ee-4f07-9637-e2466fc84852 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}